As a basic predictive marker and important prognostic factor for endocrine therapy [12], PR has been well known in early breast cancer and previous first-line treatment of advanced breast cancer, but whether it can predict the survival benefit of patients with CDK4/6 inhibitors combined with endocrine therapy is still limited. Here, CDK4 is linked to breast carcinoma.